Study of Mogamulizumab + MEDI4736 (Durvalumab) and Mogamulizumab + Tremelimumab in Subjects w/ Advanced Solid Tumors

Inclusion Criteria:

- Age ≥ 18 years;

- Locally advanced or metastatic solid tumors;

- Histologically or cytologically confirmed disease;

- Failed or were intolerant to at least one prior systemic treatment regimen with oral
or IV medications and have no additional therapy options known to prolong survival
with the exception of PD-1 or PD-L1 blockade therapy for subjects who will be enrolled
in treatment arm A. Subjects with non-small cell lung cancer must have received at
least one platinum doublet regimen. Subjects with known epidermal growth factor
receptor tyrosine kinase inhibitor activating mutations or anaplastic lymphoma kinase
rearrangement must have also exhausted approved targeted therapy options;

- The subject has a tumor suitable for biopsy and is willing to undergo tumor biopsy,
preferably of the primary tumor, within 28 days prior to Cycle 1/Visit Day 1;

Exclusion Criteria:

- Any concurrent chemotherapy, biologic, hormonal, radiation, or investigative therapy
for cancer treatment within 21 days prior prior or within 6 weeks prior to Cycle
1/Visit Day 1 for nitrosoureas or mitomycin C;

- Concurrent or prior use of immunosuppressive medication within 28 days;

- Active or prior documented autoimmune, or inflammatory bowel disease, or inflammatory
bowel disease. or systemic treatment for psoriasis within the past 5 years.;

- Prior hypersensitivity reaction to monoclonal antibodies, other therapeutic proteins,
or immunotherapy.